2018-003688-73: A Phase 1 clinical trial to test the safety, preliminary effects of increasing doses of AZD7648 alone and in combination with other anti-cancer agents in patients with advanced cancers.. |
|
|
| Not yet recruiting | 1/2 | 230 | Europe | AZD7648, Pegylated liposomal doxorubicin 2mg/ml, Olaparib 100 mg, Olaparib 150 mg, AZD7648, Film-coated tablet, Concentrate for solution for infusion, Caelyx®, Lynparza | AstraZeneca AB, AstraZeneca AB | Advanced Malignancies, Advanced solid cancers, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 1 | 30 | Europe | AZD1390 + radiotherapy, AZD1390 + durvlaumab + radiotherapy | The Netherlands Cancer Institute, Leiden University Medical Center, University Medical Center Nijmegen | Soft Tissue Sarcoma Adult | 03/26 | 07/28 | | |
